Abstract:Biosimilar development refers to the process of creating a biologic drug that is similar to an existing approved biologic drug, also known as a reference drug. Due to the complex nature of biologics drugs and the inherent variability in their manufacturing process biosimilars are not identical but highly similar to the reference drug in terms of quality, safety, and efficacy. Efficacy and safety trials for biosimilars involve large numbers of patients to confirm comparable clinical performance of the biosimilar and the reference product in appropriately sensitive clinical indications and for appropriate sensitive endpoints. The objective of a biosimilar clinical data is to address slight differences observed at previous steps and to confirm comparable clinical performance of the biosimilar and the reference product. In recent years with advances in big data computing, there has been increasing interest to incorporate the totality of information from different data sources (e.g. Real World data and published literature) in design and conduct of clinical trial to support regulatory objectives. The biosimilar development is an ideal framework for utilization of Real-World Evidence in design of trials as potentially large amount of data are available for the reference dug. Hence there may be an opportunity to use RWD in establishing, improving or validating equivalence margins (EQM) for biosimilar designs, specifically in the case there is no historical published data in the intended sensitive population. In this article, we propose a variation of matching method that seems promising to identify the matched set from a real-world data for which the effect size of targeted endpoint would be comparable to historical data. We believe this is a reasonable approach because in design stage, we can view covariates and secondary endpoints as data feature that can be used in a matching method. This approach was illustrated through a case study which indicated the estimate of the primary endpoint is within 1% of published results and thus RWD may be used to justify or estimate the equivalence margin. To ensure consistent results we recommend using this approach in different indications and endpoint scenarios. Thus utilization of RWD/RWE can provide an important opportunity to increase access to biologic therapies, reducing cost by repurposing existing data.

A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases

Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions

Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases

Reality check: Real-world evidence to support therapeutic development in hematologic malignancies

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

Real-World Evidence: A Primer

Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

On the use of RWD in support of regulatory submission in drug development

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making

Examining the Use of Real‐World Evidence in the Regulatory Process

The Use of Real-World Data/evidence in Regulatory Submissions.

Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment

Real-world evidence for coverage determination of treatments for rare diseases

Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?

Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study

[The role of real-world evidence for the study of rare diseases epidemiology and the post-marketing evaluation of orphan drugs]

From real world data to real world evidence to improve outcomes in neuro-ophthalmology

A Review and Comparative Case Study Analysis of Real-World Evidence in European Regulatory and Health Technology Assessment Decision Making for Oncology Medicines

Utility of real-world evidence in biosimilar development